Very recently, the same authors reported on compound 18, which exhibited potent BTK inhibitory activity (IC50 = 45 nM) and enhanced antiproliferative activity compared to Ibrutinib against MCL cell lines (IC50 values lower than 1 μM). The gene discussed is BTK; the disease is mantle cell lymphoma.